Statera Biopharma, Inc.
DelistedCIK 1318641fmd_0VAH59JRM150KG4JC95J6DAANYManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 02, 2009 to Sep 30, 2022, 51 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | 1 | 1 | 0 | 1 |
| Cost of revenue | – | – | – | – | – | – | – | – | 0 | 0 |
| Realized investment gains (losses) | – | – | 0 | (1) | (0) | 0 | – | – | – | – |
| Gross profit | – | – | – | – | – | – | – | – | 0 | 1 |
| Research and development | 23 | 20 | 10 | 7 | 6 | 5 | 4 | 2 | 5 | 12 |
| Selling, general and administrative | 11 | – | – | – | – | – | – | – | 5 | 20 |
| Total operating expenses | 34 | 32 | 18 | 13 | 10 | 8 | 6 | 3 | 11 | 99 |
| Operating income | (30) | (23) | (14) | (11) | (6) | (6) | (5) | (2) | (11) | (98) |
| Interest expense | – | – | 1 | 1 | 0 | – | – | – | – | – |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 8 | 3 | 14 | (2) | 4 | (4) | 1 | (0) | (2) | (4) |
| Income before taxes | (22) | (20) | 0 | (13) | (3) | (10) | (4) | (3) | (12) | (36) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (22) | (20) | 0 | (13) | (3) | (10) | (4) | (3) | (12) | (36) |
| Net income | (18) | (17) | 0 | (13) | (3) | (10) | (4) | (3) | (12) | (102) |
| Net income to common shareholders | (18) | (17) | 2 | (13) | (3) | (10) | (4) | – | – | – |